MLNT stock forecast
Our latest prediction for Melinta Therapeutics, Inc.'s stock price was made on the May 29, 2018 when the stock price was at 6.30$.
In the short term (2weeks), MLNT's stock price should outperform the market by 4.59%. During that period the price should oscillate between -9.57% and +15.39%.
In the medium term (3months), MLNT's stock price should outperform the market by 0.84%. During that period the price should oscillate between -21.41% and +42.98%.Get email alerts
Create a solid portfolio with MLNT
About Melinta Therapeutics, Inc.
Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.
At the moment the company generates 96M USD in revenues.
On its last earning announcement, the company reported a loss of -14.70$ per share.
The book value per share is 4.66$
Three months stock forecastMay 29, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|